Biotech

WaveStudio

WaveStudio Raises $125M Series B to Transform Biotech

$125M Series B
Total Raised
Series
Latest Round
2020
Founded
100-250
Employees
Austin, TX
1 min read

Quick Facts

Valuation
$250M
Latest Round Size
$125M Series B
Latest Round Date
October 2025

WaveStudio Raises $125M Series B in Latest Funding Round

WaveStudio has successfully closed a $125M Series B funding round, marking a significant milestone in the company's growth trajectory. The round was led by Greylock Partners, with participation from Sequoia Capital.

Company Overview

Founded in 2020 and headquartered in Austin, TX, WaveStudio has established itself in the Biotech space. Leading machine learning platform automating enterprise workflows with advanced AI models

With a current valuation of $250M, the company has demonstrated strong market traction and investor confidence.

Investment Details

  • Amount Raised: $125M Series B
  • Valuation: $250M
  • Lead Investor: Greylock Partners

Future Outlook

As WaveStudio moves forward with its expanded funding, the company is well-positioned to capitalize on market opportunities and drive innovation in the biotech space.

Key Investors

Greylock Partners
Venture Capital
Leading venture capital firm investing in technology companies
Sequoia Capital
Venture Capital
Leading venture capital firm investing in technology companies

About the Author

Sarah Kim
Sarah Kim
Healthcare and biotech investment analyst with expertise in Series B+ rounds and strategic partnerships.